A Universal Biomarker
for cancer
Travera is using a breakthrough technology to measure which cancer drugs work against each individual’s unique cancer cells. We are developing a universal biomarker for enabling oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs.
About Us
Travera was founded in 2017 to commercialize a breakthrough measurement technology and biomarker developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT).
What’s New at Travera
New publication supports Travera’s technology for predicting optimal treatment for cancer patients
MEDFORD, MASSACHUSETTS – November 2, 2021 – Travera announced today the publication of the results of a study which confirms the potential clinical utility of the company's testing approach to predicting a patient's response to cancer drugs based on subtle changes in...
Travera receives CLIA certification for its cancer biomarker testing laboratory
MEDFORD, MASSACHUSETTS – October 26, 2021 – Travera announced today that it has received certification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA)...
Travera raises $5.5M Series A Extension led by Khosla Ventures
MEDFORD, MASSACHUSETTS – July 15, 2021 – Travera, Inc. has announced that it has recently closed a $5.5 million Series A Extension. The financing was led by Khosla Ventures and joined by existing investor Horizons Ventures and a new investor in the company, MSA...
Read our white paper
Travera’s solution is to try drugs on the OUTSIDE of the patient rather than INSIDE. That is, remove some of the cancer cells from the patient and apply the drugs to these removed (“ex vivo”) cancer cells. We can then try many different cancer drugs (in very small quantities) against these cancer cells. This approach completely eliminates toxicity, dramatically reduces the cost (because we only need enough drug to treat a few cells, not a whole person), and only takes a couple of days.
.
Click here to download the white paper
Patient Testimonial
“While the introduction of several novel agents and regimens for newly diagnosed multiple myeloma and relapsed/refractory multiple myeloma has improved outcomes, it has also increased the complexity of treatment selection since not all patients respond. Having a test that can prospectively assess an individual’s personalized response is a much needed breakthrough for patients with multiple myeloma.”
Jack Aiello
Patient advocate and multiple myeloma survivor
